Inogen IncINGNEarnings & Financial Report
Inogen Inc is a medical technology firm specializing in the development, production and distribution of portable oxygen concentrators and associated respiratory care products. It caters primarily to patients with chronic respiratory conditions needing long-term oxygen therapy across North America, Europe and other global markets, focusing on home care and ambulatory patient segments to enhance users' quality of life.
INGN Q4 FY2025 Key Financial Metrics
Revenue
$68.6M
Gross Profit
$35.2M
Operating Profit
$-9.3M
Net Profit
N/A
Gross Margin
51.4%
Operating Margin
-13.6%
Net Margin
N/A
YoY Growth
3.4%
EPS
$-0.26
Inogen Inc Q4 FY2025 Financial Summary
Inogen Inc reported revenue of $68.6M (up 3.4% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $33.3M, operating expenses totaled $44.5M.
Key Financial Metrics
| Total Revenue | $68.6M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 51.4% |
| Operating Margin | -13.6% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Inogen Inc Q4 FY2025 revenue of $68.6M breaks down across 2 segments, led by Other at $36.1M (52.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $36.1M | 52.6% |
| Non Us | $32.5M | 47.4% |
Inogen Inc Revenue by Segment — Quarterly Trend
Inogen Inc revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Non Us) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Other | $36.1M | $25.1M | $22.8M | $18.2M |
| Non Us | $32.5M | — | — | — |
Inogen Inc Annual Revenue by Year
Inogen Inc annual revenue history includes year-by-year totals (for example, 2025 revenue was $295.3M).
Inogen Inc Quarterly Revenue & Net Profit History
Inogen Inc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $68.6M | +3.4% | N/A | N/A |
| Q3 FY2025 | $79.1M | +5.6% | $-5.3M | -6.7% |
| Q2 FY2025 | $79.2M | +6.4% | $-4.2M | -5.2% |
| Q1 FY2025 | $68.5M | +8.5% | $-6.2M | -9.0% |
| Q4 FY2024 | $66.3M | +11.6% | N/A | N/A |
| Q3 FY2024 | $74.9M | +10.2% | $-6.0M | -8.0% |
| Q2 FY2024 | $74.4M | +8.9% | $-5.6M | -7.5% |
| Q1 FY2024 | $63.1M | +12.9% | $-14.6M | -23.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $63.1M | $74.4M | $74.9M | $66.3M | $68.5M | $79.2M | $79.1M | $68.6M |
| YoY Growth | 12.9% | 8.9% | 10.2% | 11.6% | 8.5% | 6.4% | 5.6% | 3.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $315.6M | $308.9M | $306.2M | $296.2M | $308.4M | $312.0M | $307.0M | $298.6M |
| Liabilities | $123.7M | $121.3M | $120.8M | $122.3M | $110.5M | $112.5M | $109.8M | $106.4M |
| Equity | $191.9M | $187.6M | $185.4M | $173.9M | $198.0M | $199.5M | $197.2M | $192.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.7M | $6.7M | $7.0M | $-3.0M | $-16.8M | $4.3M | $2.2M | $-943000 |